AI Clinical Research Advisor: From Protocol Design to FDA Submission

Clinical Research Advisor helps you design, review, and de-risk clinical studies by matching the research question to a defensible design, a workable protocol, and a realistic FDA, EMA, or ICH pathway. While trial teams still spend weeks reconciling endpoints, eligibility, monitoring, and consent language across conflicting drafts, this AI provides methodologist-level counsel from concept through analysis and reporting.

✅ Protocol and estimand review aligned to current GCP expectations ✅ Regulatory pathway framing for IND, CTA, devices, rare disease, and RWE ✅ Operational checks on recruitment, visit burden, and site feasibility ✅ Safety, DSMB, consent, and reporting guidance for investigators and sponsors

To understand why this matters, consider what trial teams are being asked to do at once: adopt quality-by-design under revised GCP, run multinational applications through a single EU portal, and still enroll representative participants without writing a protocol no site can execute.

Quick Answer: What Is Clinical Research Advisor?

Clinical Research Advisor is an AI clinical methodologist that helps teams design, review, and report human studies from proof-of-concept through pivotal and post-market work. It advises principal investigators, sponsors, coordinators, biostatisticians, and regulatory staff on design, GCP, and submissions.

Key capabilities:

• Match study design to the question, jurisdiction, and site constraints
• Review protocols for estimands, endpoints, multiplicity, and missing data
• Map FDA, EMA, PMDA, NMPA, and ICH pathways before you lock a protocol
• Flag operational, ethics, and safety gaps a reviewer or IRB is likely to raise

Why Clinical Trial Design Is Harder Than the Template Suggests

A protocol is no longer a static document you write once and monitor against a checklist. ICH E6(R3) Good Clinical Practice, adopted as a Step 4 guideline on 6 January 2025, asks sponsors to identify critical-to-quality factors, use risk-proportionate controls, and write protocols that are operationally feasible. The coming-into-effect date is 23 July 2025. That shift rewards teams who design quality in, and it penalizes protocols that are internally inconsistent, over-complex, or silent on how deviations will be handled.

The European side of the same problem is structural. The EU Clinical Trials Regulation became fully applicable on 31 January 2025, and sponsors must use the Clinical Trials Information System (CTIS) for applications and oversight. Under the Regulation, sponsors can apply in up to 30 European countries with one online submission. Trials still running under the old Directive were required to transition into CTIS by 31 January 2025. A protocol that cannot survive that coordinated assessment will stall even if the science is sound.

But accessing this level of design and regulatory judgment is frustratingly difficult:

• Senior trialists and regulatory strategists are scarce, expensive, and booked around submission deadlines.
• Generic AI tools can draft protocol prose without knowing when a non-inferiority margin, an estimand, or a diversity plan will draw an FDA or ethics question.
• Rare-disease and precision programs often cannot use a textbook Phase 3 template, yet they still need a design a regulator can defend.
• Coordinators and junior statisticians are left translating high-level advice into visit schedules, consent language, and SAE clocks.

About 75 percent — of rare disease trials fail, and workshop testimony to the National Academies attributed only about 15–20 percent of those failures to the science. Recruitment and retention were the dominant cause.

90 percent — of rare diseases affect fewer than 150 patients, which makes a conventional double-blind, placebo-controlled sample-size target operationally impossible for most of that landscape.

Representation is a separate, persistent failure mode. A National Academies workshop on person-centered cancer research noted that enrollment rates have improved across demographic groups, yet they still do not reflect cancer incidence in those populations. Restrictive eligibility, visit burden, and consent that patients cannot actually use all show up later as slow enrollment, amendments, and weak generalizability.

Decentralized and hybrid models add another layer of design debt. Market analyses project the decentralized and digitalized clinical trials market to exceed $9.36 billion by 2026. That growth does not automatically make a remote visit schedule, local lab plan, or digital endpoint fit-for-purpose. It only raises the cost of getting those elements wrong.

This is exactly what Clinical Research Advisor was built for.

Why Clinical Research Advisor

Clinical Research Advisor treats the protocol as a scientific, regulatory, and operational document at the same time. You bring a concept, a draft, or a stuck decision — phase, indication, comparator, jurisdiction — and it returns a recommended design with the trade-offs a reviewer would actually argue about.

It is built for the people who have to live with the protocol: investigators who need a defensible primary endpoint, sponsors who need a pathway, biostatisticians who need an estimand before an analysis method, and coordinators who need procedures that sites can follow.

Traditional Approach	Clinical Research Advisor
Sequential handoffs among medical writing, stats, regulatory, and operations	One design conversation covering science, GCP, and site feasibility
Template protocols that accumulate amendments after first-patient-in	Early flags on eligibility, visit burden, missing-data, and stopping rules
Generic chatbot drafts that skip ICH E9(R1) estimands and multiplicity	Estimand-first statistical framing with ITT, per-protocol, and sensitivity options
External consultants booked in week-long cycles	Immediate iteration on protocol language, consent, and submission strategy
Guidance documents read in isolation	Cross-walk of FDA, EMA/CTIS, and ICH expectations for the study you are actually running

Design that matches the question, not the fashion

The advisor will recommend a parallel-group randomized trial when that is the honest confirmatory design. It will also tell you when a crossover, factorial, cluster, non-inferiority, platform, basket, pragmatic, decentralized, or externally controlled study is the better fit — and what bias, power, or regulatory acceptance you are trading.

"We have a first-in-human monoclonal antibody for moderate-to-severe atopic dermatitis. Help me choose between a multiple-ascending-dose design with sentinel dosing versus an adaptive dose-finding scheme, and tell me what FDA would likely ask in a pre-IND meeting."

Protocol and estimand review, not just copy editing

E6(R3) expects a clear, concise, operationally feasible protocol that states objectives, estimands when defined, bias-control measures, stopping rules, and how missing and intercurrent-event data will be handled. The advisor reviews drafts against that structure: primary and key secondary endpoints, randomization and blinding, analysis populations, DSMB rules, and whether each exclusion criterion has a scientific or safety reason to exist.

"Review this Phase 3 heart-failure protocol. Primary endpoint is a five-component composite. Identify estimand issues, multiplicity risk, and operational problems that will slow enrollment."

Regulatory strategy without paralysis

US programs still turn on IND, NDA/BLA, and device pathways under FDA rules; EU programs now run through CTIS under the Clinical Trials Regulation. The advisor frames pre-IND versus scientific advice, orphan and expedited designations, and when real-world evidence is a supplement rather than a substitute for randomization. It also distinguishes requirements from preferences, so you do not over-build a Phase 2 protocol to look like a label-enabling trial.

"Map the US and EU path for a PMA-class diagnostic used to select patients for a companion therapeutic. What clinical evidence do we need before a pre-sub, and where does a decentralized sample-collection model create new questions?"

North America spending on AI in clinical trials is already material — estimated at $0.80 billion in 2025 — which makes it more important to use AI that argues like a trialist, not a summarizer of last year's guidance PDFs.

How It Works

Step 1: State the study and the decision you need Open Clinical Research Advisor and describe the indication, intervention, phase, population, and jurisdiction. Include what is already locked (comparator, primary endpoint, sample size) and what is still open. The more operational detail you give — visit burden, competing trials, rare-disease prevalence — the more precise the design recommendation.

"Phase 2b, oral JAK inhibitor vs. placebo in adults with active ankylosing spondylitis, US and EU, 24-week primary readout. We are debating ASDAS versus MRI inflammation as primary. Enrollment target is 180."

Step 2: Get a ranked design and regulatory frame The advisor returns a recommended design with why it fits, what a reviewer may challenge, and which alternatives are still viable. You should expect a view on randomization, blinding, estimand, sample-size assumptions, and whether the pathway is a standard IND/CTA, an expedited program, or a device/RWE hybrid.

If you also need published precedent on endpoints or historical controls, Academic Research Assistant can pull current literature across major databases so the design conversation is grounded in actual trials, not memory.

Step 3: Pressure-test the protocol, SAP, and consent Paste a protocol section, SAP outline, or informed-consent draft. The review focuses on internal contradictions, missing stopping rules, over-restrictive eligibility, unvalidated PROs, and consent language that will not survive an IRB or a participant who is reading at a general-public level. ICH E6(R3) treats informed consent as an ongoing process that can include remote and digital interactions, not a one-time signature.

"Here is our eConsent flow for a 36-month Alzheimer prevention trial. Flag comprehension risk, re-consent triggers, and what we still need for a legally authorized representative pathway."

Step 4: Translate the design into operations and safety Ask for a schedule of assessments critique, risk-based monitoring plan, SAE/SUSAR clock reminder, or DSMB charter outline. The point is to catch the protocol that is scientifically elegant and operationally impossible — too many blood draws, too many screen fails, no quality-tolerance limits, no plan for missing visits.

Step 5: Prepare the next regulatory or reporting move Use the same thread for pre-IND questions, CTIS application structure, ClinicalTrials.gov registration timing, or CONSORT-style results reporting. The advisor will not file your IND or CTA; official submissions still go through FDA ESG, CTIS, and your regulatory counsel. It will tell you what those reviewers are likely to ask, and what to fix before you spend a cycle finding out the hard way.

Try Clinical Research Advisor free — no credit card required.

Results & Use Cases

📊 Investigator designing a first registration trial

Scenario: An academic PI has promising Phase 2 data in a biomarker-selected solid tumor and needs a Phase 3 design that FDA will accept as clinically meaningful.

Traditional Approach: Months of consulting time, conflicting advice on PFS versus OS, and a protocol that later needs a substantial amendment after the first Type B meeting.

Clinical Research Advisor: A documented recommendation on primary endpoint, intercurrent-event handling, multiplicity for key secondaries, and a pre-IND question list — including where a diversity action plan and PRO strategy will be expected.

• Makes the estimand explicit before the SAP is written
• Separates labeling claims from exploratory analyses
• Anticipates reviewer objections on composites and surrogate endpoints

When that same PI needs a structured evidence synthesis of prior checkpoint-inhibitor trials, Literature Review Assistant can turn the question into a review protocol rather than a pile of PDFs.

💼 Sponsor choosing US versus EU first-in-human strategy

Scenario: A biotech is planning a first-in-human study and cannot afford a protocol that is acceptable in one region and incomplete in the other.

Traditional Approach: Parallel regulatory vendors, duplicated briefing books, and late discovery that EU CTR transparency or US IND safety-reporting clocks were never designed into the operations plan.

Clinical Research Advisor: Side-by-side pathway advice — pre-IND versus EMA scientific advice, what belongs in the protocol versus the IB, and how CTIS multinational assessment changes timelines relative to a US-only IND.

• Keeps participant protection and data reliability as design constraints, not appendix items
• Flags when an adaptive or Bayesian feature needs simulation and pre-specification
• Distinguishes “must” requirements from “nice to have” gold-plating

📱 Coordinator managing amendments and safety on the road

Scenario: A study coordinator is between site visits, on a phone, and needs a fast, correct answer: is this a substantial amendment, does this AE meet SAE criteria, and what is the reporting clock.

Traditional Approach: Digging through an outdated SOP binder or waiting for medical monitor email while the clock runs.

Clinical Research Advisor: Mobile, same-session guidance on amendment classification logic, causality documentation, and the difference between sponsor notification and SUSAR timelines — with the reminder that local SOPs and the protocol still govern.

• Works on web, iOS, and Android with synced history
• Remembers the study context so you are not re-explaining the indication every time
• Gives procedural clarity coordinators can act on, then escalate

If the underlying issue is that the program still lacks a fundable research plan, Research Proposal Writer can help turn the same design decisions into a sponsor- or funder-ready proposal without losing the methodological core.

🎯 Biostatistician locking an estimand before sample size

Scenario: The medical team wants a treatment-policy estimand; operations know rescue medication will be common; the statistician needs a sample size that is not based on an optimistic effect size.

Traditional Approach: Sample size calculated on expected effect, dropout ignored, and sensitivity analyses added after database lock.

Clinical Research Advisor: Walks through ICH E9(R1) components — population, variable, intercurrent events, summary measure — then stress-tests power, dropout inflation, and what happens if the MCID is smaller than the hoped-for delta.

• Pushes MCID-based thinking over optimism
• Makes multiplicity and interim alpha-spending visible early
• Keeps ITT, per-protocol, and safety populations from being defined after unblinding

FAQ

What is Clinical Research Advisor used for?

Clinical Research Advisor is used to design and review clinical studies involving human participants. Typical work includes choosing a trial design, drafting or critiquing protocol sections, specifying estimands and endpoints, planning safety monitoring, and framing FDA or EMA submission strategy. It supports investigators, sponsors, coordinators, biostatisticians, regulatory professionals, and students.

Is Clinical Research Advisor free?

Yes. You can use Clinical Research Advisor on the free tier with core features and limited monthly usage. Paid plans increase usage — Plus starts at $20 per month — and usage resets in full on each billing date. No credit card is required to start.

How is this different from a general chatbot or a CRO template?

General models can write fluent protocol language. They often miss the decisions that actually fail trials: unjustified exclusions, composites that hide component inconsistency, non-inferiority margins copied from the wrong indication, or consent that an IRB will reject. This advisor is built around trial methodology, ICH GCP, and operational realism. It will recommend a simple parallel RCT when that is stronger science than a fashionable adaptive design.

Can Clinical Research Advisor write a full protocol or file my IND?

It can draft and review protocol sections, SAP outlines, consent language, DSMB charter structure, and briefing-document questions. Complete protocols are long, multi-author documents; the practical workflow is section-by-section review with your medical, stats, and regulatory team. It does not submit to FDA ESG, CTIS, or ethics committees, and it is not a substitute for qualified regulatory counsel.

Does Clinical Research Advisor work on mobile?

Yes. It runs with full feature parity on web, iOS, and Android, including speech-to-text. That matters for coordinators and investigators who need a design or safety answer between clinic blocks, not only at a desktop EDC terminal.

How current and reliable is the regulatory advice?

Regulatory guidance moves quickly. The advisor is built to verify current FDA, EMA, and ICH positions when the question depends on a date, fee, portal, or recently revised guideline — including E6(R3) quality-by-design and EU CTR/CTIS obligations. FDA discussions of E6(R3) have emphasized proportionate, risk-based trial design. Even so, treat the output as expert input to your team, then confirm binding requirements with your regulatory affairs group and the agency.

Conclusion

Clinical trial failure is often a design and operations problem, not a molecule problem. Revised GCP, a fully applicable EU Clinical Trials Regulation, and persistent recruitment gaps mean a protocol has to be scientifically tight, regulator-ready, and executable at the site — at the same time.

Clinical Research Advisor gives investigators and sponsors a dedicated AI methodologist for that work: study design, protocol and estimand review, FDA and EMA pathway planning, and the ethics and safety architecture that keeps participants first. Use it to pressure-test the protocol before the first amendment, not after.

Try Clinical Research Advisor now. Explore more at Jenova.

---

For Developers: Clinical Research Advisor is available programmatically via the Jenova API — integrate clinical trial design and regulatory strategy into your application with a single API call. Full documentation →